A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myelomaAlessandra Larocca, Antonio Palumbo, Oreste Villani et al.|Leukemia|2016Cited by 46
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Paola Omedè, Manuela Gambella et al.|Oncotarget|2016Cited by 36
Resistance of papillary thyroid cancer stem cells to chemotherapyRaffaella Giuffrida, Concetta Conticello|Oncology Letters|2016Cited by 32